Lactoferrin inhibits the proliferation of IMR‑32 neuroblastoma cells even under X‑rays

Kato,Shinya

doi:10.3892/mi.2023.93

Lactoferrin inhibits the proliferation of IMR‑32 neuroblastoma cells even under X‑rays

Authors:
- Shinya Kato
View Affiliations

Affiliations: Radioisotope Experimental Facility, Advanced Science Research Promotion Center, Mie University, Tsu, Mie 514‑8507, Japan
Published online on: June 26, 2023 https://doi.org/10.3892/mi.2023.93
Article Number: 33
Copyright : © Kato . This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neuroblastoma is a typical solid tumor common in childhood. The present study investigated the inhibitory effects of lactoferrin on the proliferation of IMR‑32 neuroblastoma cells, including under X‑ray irradiation. In controlled in vitro assays, it was found that lactoferrin inhibited cell proliferation, accompanied by cell membrane disruption. Furthermore, intracellular reactive oxygen species generation increased in IMR‑32 cells treated with lactoferrin, causing membrane lipid peroxidation and the leakage of lactate dehydrogenase. The IC₅₀ values for cell proliferation were ~2.0 nM for doxorubicin, 2.7 mM for dibutyryl‑cAMP and 45.9 µM for lactoferrin. X‑ray irradiation at 1 Gy decreased cell proliferation to ~30%, which was not restored by lactoferrin. In the Fenton reaction system with iron chloride, lactoferrin increased hydroxyl radical (OH·) formation via H₂O₂, as confirmed by electron spin resonance spectra. On the whole, the findings of the present study indicate that lactoferrin, found abundantly in milk, may help prevent or treat neuroblastoma in infants with modest efficacy, and does not exert a protective effect against X‑rays.

View Figures

View References

1	Ertugrul MS, Nadaroglu H, Nalci OB, Hacimuftuoglu A and Alayli A: Preparation of CoS nanoparticles-cisplatin bio-conjugates and investigation of their effects on SH-SY5Y neuroblastoma cell line. Cytotechnology. 72:885–896. 2020.PubMed/NCBI View Article : Google Scholar : (Epub ahead of print).
2	Ito R, Asami S, Kagawa S, Motohashi S, Shichino H, Chin M, Yoshida Y, Nemoto N, Mugishima H and Suzuki T: Usefulness of tyrosine hydroxylase mRNA for diagnosis and detection of minimal residual disease in neuroblastoma. Biol Pharm Bull. 27:315–318. 2004.PubMed/NCBI View Article : Google Scholar
3	Qiao Y, Sunada NK, Hatada AE, Lange I, Khutsishvili M, Alizade V, Atha D, Ko'omoa-Lange DL and Borris RP: Potential anti-neuroblastoma agents from Juniperus oblonga. Biochem Biophys Res Commun. 516:733–738. 2019.PubMed/NCBI View Article : Google Scholar
4	Pohl A, Erichsen M, Stehr M, Hubertus J, Bergmann F, Kammer B and von Schweinitz D: Image-defined risk factors correlate with surgical radicality and local recurrence in patients with neuroblastoma. Klin Padiatr. 228:118–123. 2016.PubMed/NCBI View Article : Google Scholar
5	Boyd JE, Parmley RT, Langevin AM and Saldívar VA: Neuroblastoma presenting as acute monoblastic leukemia. J Pediatr Hematol Oncol. 18:206–212. 1996.PubMed/NCBI View Article : Google Scholar
6	Zheng T, Ménard M and Weiss WA: Neuroblastoma metastases: Leveraging the avian neural crest. Cancer Cell. 32:395–397. 2017.PubMed/NCBI View Article : Google Scholar
7	London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, Thorner P, Brodeur G, Maris JM, Reynolds CP and Cohn SL: Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the children's oncology group. J Clin Oncol. 23:6459–6465. 2005.PubMed/NCBI View Article : Google Scholar
8	Tumilowicz JJ, Nichols WW, Cholon JJ and Greene AE: Definition of a continuous human cell line derived from neuroblastoma. Cancer Res. 30:2110–2118. 1970.PubMed/NCBI
9	Imashuku S, Inui A, Nakamura T, Tanaka J and Miyake S: Catecholamine metabolism in tissue culture cells of a neuroblastoma. J Clin Endocrinol Metab. 36:931–936. 1973.PubMed/NCBI View Article : Google Scholar
10	Ji B, Maeda J, Higuchi M, Inoue K, Akita H, Harashima H and Suhara T: Pharmacokinetics and brain uptake of lactoferrin in rats. Life Sci. 78:851–855. 2006.PubMed/NCBI View Article : Google Scholar
11	Sriramoju B, Kanwar RK and Kanwar JR: Lactoferrin induced neuronal differentiation: A boon for brain tumours. Int J Dev Neurosci. 41:28–36. 2015.PubMed/NCBI View Article : Google Scholar
12	Feng L, Li J, Qin L, Guo D, Ding H and Deng D: Radioprotective effect of lactoferrin in mice exposed to sublethal X-ray irradiation. Exp Ther Med. 16:3143–3148. 2018.PubMed/NCBI View Article : Google Scholar
13	Nishimura Y, Homma-Takeda S, Kim HS and Kakuta I: Radioprotection of mice by lactoferrin against irradiation with sublethal X-rays. J Radiat Res. 55:277–282. 2014.PubMed/NCBI View Article : Google Scholar
14	Wei YL, Xu JY, Zhang R, Zhang Z, Zhao L and Qin LQ: Effects of lactoferrin on X-ray-induced intestinal injury in Balb/C mice. Appl Radiat Isot. 146:72–77. 2019.PubMed/NCBI View Article : Google Scholar
15	Kato S: Under lithium carbonate administration, nicotine triggers cell dysfunction in human glioblastoma U-251MG cells, which is distinct from cotinine. Med Int (Lond). 2(19)2022.PubMed/NCBI View Article : Google Scholar
16	Kato S: Effects of platinum-coexisting dopamine with X-ray irradiation upon human glioblastoma cell proliferation. Hum Cell. 34:1653–1661. 2021.PubMed/NCBI View Article : Google Scholar
17	Zaatiti H, Abdallah J, Nasr Z, Khazen G, Sandler A and Abou-Antoun TJ: Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration. Int J Oncol. 52:787–803. 2018.PubMed/NCBI View Article : Google Scholar
18	Tanimoto T, Tazawa H, Ieda T, Nouso H, Tani M, Oyama T, Urata Y, Kagawa S, Noda T and Fujiwara T: Elimination of MYCN-amplified neuroblastoma cells by telomerase-targeted oncolytic virus via MYCN suppression. Mol Ther Oncolytics. 18:14–23. 2020.PubMed/NCBI View Article : Google Scholar
19	Ishiyama M, Tominaga H, Shiga M, Sasamoto K, Ohkura Y and Ueno K: A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull. 19:1518–1520. 1996.PubMed/NCBI View Article : Google Scholar
20	Soh N, Ariyoshi T, Fukaminato T, Nakajima H, Nakano K and Imato T: Swallow-tailed perylene derivative: A new tool for fluorescent imaging of lipid hydroperoxides. Org Biomol Chem. 5:3762–3768. 2007.PubMed/NCBI View Article : Google Scholar
21	Wu L, Oshima T, Shan J, Sei H, Tomita T, Ohda Y, Fukui H, Watari J and Miwa H: PAR-2 activation enhances weak acid-induced ATP release through TRPV1 and ASIC sensitization in human esophageal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 309:G695–G702. 2015.PubMed/NCBI View Article : Google Scholar
22	Baehner RL and Nathan DG: Leukocyte oxidase: Defective activity in chronic granulomatous disease. Science. 155:835–836. 1967.PubMed/NCBI View Article : Google Scholar
23	Choi HS, Kim JW, Cha YN and Kim C: A quantitative nitroblue tetrazolium assay for determining intracellular superoxide anion production in phagocytic cells. J Immunoassay Immunochem. 27:31–44. 2006.PubMed/NCBI View Article : Google Scholar
24	Elfinger M, Maucksch C and Rudolph C: Characterization of lactoferrin as a targeting ligand for nonviral gene delivery to airway epithelial cells. Biomaterials. 28:3448–3455. 2007.PubMed/NCBI View Article : Google Scholar
25	Suzuki YA, Lopez V and Lönnerdal B: Mammalian lactoferrin receptors: Structure and function. Cell Mol Life Sci. 62:2560–2575. 2005.PubMed/NCBI View Article : Google Scholar
26	Bi C, Wang A, Chu Y, Liu S, Mu H, Liu W, Wu Z, Sun K and Li Y: Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson's disease treatment. Int J Nanomedicine. 11:6547–6559. 2016.PubMed/NCBI View Article : Google Scholar
27	Bannister JV, Bannister WH, Hill HA and Thornalley PJ: Enhanced production of hydroxyl radicals by the xanthine-xanthine oxidase reaction in the presence of lactoferrin. Biochim Biophys Acta. 715:116–120. 1982.PubMed/NCBI View Article : Google Scholar
28	Klebanoff SJ and Waltersdorph AM: Prooxidant activity of transferrin and lactoferrin. J Exp Med. 172:1293–1303. 1990.PubMed/NCBI View Article : Google Scholar
29	Pietrantoni A, Ammendolia MG, Tinari A, Siciliano R, Valenti P and Superti F: Bovine lactoferrin peptidic fragments involved in inhibition of echovirus 6 in vitro infection. Antiviral Res. 69:98–106. 2006.PubMed/NCBI View Article : Google Scholar
30	Chung TDY and Raymond KN: Lactoferrin: The role of conformational changes in its iron binding and release. J Am Chem Soc. 115:6765–6768. 1993.
31	Lorget F, Clough J, Oliveira M, Daury MC, Sabokbar A and Offord E: Lactoferrin reduces in vitro osteoclast differentiation and resorbing activity. Biochem Biophys Res Commun. 296:261–266. 2002.PubMed/NCBI View Article : Google Scholar
32	Gibbons JA, Kanwar JR and Kanwar RK: Iron-free and iron-saturated bovine lactoferrin inhibit survivin expression and differentially modulate apoptosis in breast cancer. BMC Cancer. 15(425)2015.PubMed/NCBI View Article : Google Scholar
33	Shoji H, Oguchi S, Shinohara K, Shimizu T and Yamashiro Y: Effects of iron-unsaturated human lactoferrin on hydrogen peroxide-induced oxidative damage in intestinal epithelial cells. Pediatr Res. 61:89–92. 2007.PubMed/NCBI View Article : Google Scholar
34	Wakabayashi H, Matsumoto H, Hashimoto K, Teraguchi S, Takase M and Hayasawa H: Inhibition of iron/ascorbate-induced lipid peroxidation by an N-terminal peptide of bovine lactoferrin and its acylated derivatives. Biosci Biotechnol Biochem. 63:955–957. 1999.PubMed/NCBI View Article : Google Scholar